Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.7633 EUR
−38.81 M EUR
27.55 M EUR
4.02 M
About Assembly Biosciences, Inc.
Sector
Industry
CEO
Jason A. Okazaki
Website
Headquarters
South San Francisco
Founded
2005
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Related stocks
$ASMB Assembly Biosciences Ready for Reversal.
Hopefully you find the chart helpful in terms of Supports & Resistance etc.
we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice.
Thank you for taking time to consult our chart and we would really
ASMB Technical Analysis 🧙Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health
ASMB Technical Analysis 🧙Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
The current price of A402CB is 15.7500 EUR — it has increased by 0.99% in the past 24 hours. Watch Assembly Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LS exchange Assembly Biosciences, Inc. stocks are traded under the ticker A402CB.
A402CB stock has risen by 0.99% compared to the previous week, the month change is a 16.35% rise, over the last year Assembly Biosciences, Inc. has showed a 12.90% increase.
We've gathered analysts' opinions on Assembly Biosciences, Inc. future price: according to them, A402CB price has a max estimate of 27.57 EUR and a min estimate of 25.79 EUR. Watch A402CB chart and read a more detailed Assembly Biosciences, Inc. stock forecast: see what analysts think of Assembly Biosciences, Inc. and suggest that you do with its stocks.
A402CB reached its all-time high on Jun 27, 2025 with the price of 15.5500 EUR, and its all-time low was 7.3600 EUR and was reached on Apr 9, 2025. View more price dynamics on A402CB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
A402CB stock is 4.53% volatile and has beta coefficient of 1.51. Track Assembly Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Assembly Biosciences, Inc. there?
Today Assembly Biosciences, Inc. has the market capitalization of 118.52 M, it has increased by 1.47% over the last week.
Yes, you can track Assembly Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Assembly Biosciences, Inc. is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
A402CB earnings for the last quarter are −1.08 EUR per share, whereas the estimation was −1.48 EUR resulting in a 26.88% surprise. The estimated earnings for the next quarter are −1.47 EUR per share. See more details about Assembly Biosciences, Inc. earnings.
Assembly Biosciences, Inc. revenue for the last quarter amounts to 8.71 M EUR, despite the estimated figure of 6.85 M EUR. In the next quarter, revenue is expected to reach 4.50 M EUR.
A402CB net income for the last quarter is −8.15 M EUR, while the quarter before that showed −9.98 M EUR of net income which accounts for 18.36% change. Track more Assembly Biosciences, Inc. financial stats to get the full picture.
No, A402CB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 3, 2025, the company has 73 employees. See our rating of the largest employees — is Assembly Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Assembly Biosciences, Inc. EBITDA is −41.14 M EUR, and current EBITDA margin is −158.80%. See more stats in Assembly Biosciences, Inc. financial statements.
Like other stocks, A402CB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Assembly Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.